Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data

Ezra Cohen • 22 Oct 2018
ESMO 2018
Head and Neck Cancer AZD5069 Danvatirsen Durvalumab
SCORES

The SCORES trial (NCT02499328) is investigating the combination of durvalumab plus danvatirsen (a STAT3 pathway inhibitor) or AZD5069 (a CXCR2 inhibitor) for advanced solid tumors and recurrent/metastatic head and neck squamous cell carcinoma. Here, Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses the updated results of this trial, including exciting efficacy data. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Ezra Cohen

3:13
PD-L1 and alternative biomarkers in head and neck cancer
Ezra Cohen • 16 Apr 2023
1:41
The future of liquid biopsies in head and neck cancer
Ezra Cohen • 16 Apr 2023
2:01
Petosemtamab has promising activity in advanced HNSCC
Ezra Cohen • 16 Apr 2023
1:37
Mono or combination immunotherapy for HNSCC?
Ezra Cohen • 26 Oct 2018

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals